Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5932-5940

  Monfared, Parisa ^a   Winkeler, Alexandra ^a   Klein, Markus ^a   Li, Hongfeng ^a   Klose, Anke ^a   Hoesel, Marianna ^a   Waerzeggers, Yannic ^a   Korsching, Sigrun ^a   Jacobs, Andreas H ^a,b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b KLINIKUM FULDA   (Germany)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CASPASE 3; CASPASE 7; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EXPOSURE; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANIMAL; BRAIN TUMOR; DISEASE COURSE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; INSTRUMENTATION; METABOLISM; METHODOLOGY; NUDE MOUSE; RETROVIRUS; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA DAMAGE; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; RETROVIRIDAE; TRANSCRIPTION, GENETIC;

EID: 48649098193     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6373     Document Type: Article

References (50)

1. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245-6.
2. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
3. Sladek TL. E2F transcription factor action, regulation and possible role in human cancer. Cell Prolif 1997;30:97-105.
4. Lu K, Shih C, Teicher BA. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol 2000;46:293-304.
5. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002;62:1266-70.
6. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
7. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002;62:3438-47.
8. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
9. Adams PD, Kaelin WG, Jr. Transcriptional control by E2F. Semin Cancer Biol 1995;6:99-108.
10. Zwicker J, Muller R. Cell cycle-regulated transcription in mammalian cells. Prog Cell Cycle Res 1995;1:91-9.
11. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997;3:1145-9.
12. Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol 1999;14:5-14.
13. O'Connor DJ, Lu X. Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene 2000;19:2369-76.
14. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998;58:4292-6.
15. Hoshino T, Deen DF, Williams ME, Sano Y. Differential response to elutriated 9L cells to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1981;41:4404-7.
16. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001;98:9300-5.
17. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-52.
18. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-61.
19. Jacobs A, Dubrovin M, Hewett J, et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1999;1:154-61.
20. Jacobs AH, Winkeler A, Hartung M, et al. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 2003;14:277-97.
21. Tepe P, Hassenbusch SJ, Benoit R, Anderson JH. BCNU stability as a function of ethanol concentration and temperature. J Neurooncol 1991;10:121-7.
22. Aguzzi A, Brandner S, Isenmann S, Steinbach JP, Sure U. Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia 1995;15:348-64.
23. Protzer U, Seyfried S, Quasdorff M, et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology 2007;133:1156-65.
24. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
25. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004;2:203-14.
26. Hershko T, Chaussepied M, Oren M, Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 2005;12:377-83.
27. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-7.
28. Yu SF, von Ruden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 1986;83:3194-8.
29. Marty L, Roux P, Royer M, Piechaczyk M. MoMuLV-derived self-inactivating retroviral vectors possessing multiple cloning sites and expressing the resistance to either G418 or hygromycin B. Biochimie 1990;72:885-7.
30. Di Stefano L, Jensen MR, Helin K. E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J 2003;22:6289-98.
31. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 2002;62:6764-9.
32. Mathivanan J, Rohini K, Gope ML, Anandh B, Gope R. Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors. Mol Cell Biochem 2007;302:67-77.
33. Kaelin WG, Jr. E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther 2003;2:S48-54.
34. Rogoff HA, Kowalik TF. Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle 2004;3:845-6.
35. Rogoff HA, Pickering MT, Frame FM, et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol 2004;24:2968-77.
36. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001;15:1833-44.
37. Markham D, Munro S, Soloway J, O'Connor DP, La Thangue NB. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep 2006;7:192-8.
38. Fan G, Ma X, Kren BT, Steer CJ. Unbound E2F modulates TGF-β1-induced apoptosis in HuH-7 cells. J Cell Sci 2002;115:3181-91.
39. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 2004;3:1071-9.
40. Johnson DG, Degregori J. Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. Curr Mol Med 2006;6:731-8.
41. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med 2006;6:739-48.
42. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
43. Sellers WR, Rodgers JW, Kaelin WG, Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A 1995;92:11544-8.
44. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004;10:1257-60.
45. Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature 1975;254:245-7.
46. Tobey RA, Crissman HA. Comparative effects of three nitrosourea derivatives on mammalian cell cycle progression. Cancer Res 1975;35:460-70.
47. Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG. Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 2001;61:4155-9.
48. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007;67:11886-95.
49. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007;16:837-47.
50. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.